Ineffective treatment of PML with pembrolizumab
Exhausted memory T-cell subsets as a clue?
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 3, 2019
- Accepted in final form August 21, 2019
- First Published October 9, 2019.
Author Disclosures
- Marc Pawlitzki, MD*,
- Tilman Schneider-Hohendorf, PhD*,
- Leoni Rolfes, MD,
- Sven G. Meuth, MD, PhD,
- Heinz Wiendl, MD,
- Nicholas Schwab, PhD* and
- Oliver M. Grauer, MD, PhD*
- Marc Pawlitzki, MD*,
NONE
NONE
Novartis, funding for travel to conference 2014-2016 Merck Serono, funding for travel to conference 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tilman Schneider-Hohendorf, PhD*,
NONE
NONE
TSH received travel support from Novartis and Biogen.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Leoni Rolfes, MD,
NONE
NONE
(1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD,
(1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
(1) PLoS One (editor) (2) DGNeurologie, founding member editorial board
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4  1402) (3)"NR2B selective NMDA-receptor Antagonists for Treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975)
NONE
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
NONE
NONE
NONE
Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
NONE
Research is funded by Else Kröner Fresenius Foundation, Hertie Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Biogen (2) Evgen (3) Genzyme (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Actelion (3) Biogen (4) IGES (5) Johnson & Johnson (6) Novartis (7) Roche (8) Sanofi-Aventis (9) Swiss Multiple Sclerosis Society
NONE
NONE
NONE
(1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme.
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Nicholas Schwab, PhD* and
NONE
NONE
(1) Biogen, travel expenses, (2) Novartis, speaking honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) DFG CRC128 B1, starting 2012 (2) University Muenster, IMF, starting 2011 (3) PML Consortium, starting 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Oliver M. Grauer, MD, PhD*
NONE
NONE
Roche, MagForce
NONE
NONE
NONE
NONE
Gilead Sciences, Bristol-Myers-Squibb
NONE
NONE
NONE
Bristol-Myers-Squibb
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany.
- Correspondence
Dr. Grauer oliver.grauer{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathyEvelyn Dubois, Christoph Ruschil, Felix Bischof et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2015 -
Articles
Fatal PML associated with efalizumab therapyInsights into integrin αLβ2 in JC virus controlN. Schwab, J.C. Ulzheimer, R.J. Fox et al.Neurology, February 01, 2012 -
Case
Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal LeukoencephalopathyJulien Haroche, Fleur Cohen Aubart, Karima Mokhtari et al.Neurology: Clinical Practice, February 03, 2020 -
Views & Reviews
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patientsA. Venkataramana, C. A. Pardo, J. C. McArthur et al.Neurology, August 07, 2006